Literature DB >> 23430938

Zellweger Spectrum Disorder with Mild Phenotype Caused by PEX2 Gene Mutations.

Andrea Mignarri1, Claudia Vinciguerra, Antonio Giorgio, Sacha Ferdinandusse, Hans Waterham, Ronald Wanders, Enrico Bertini, Maria Teresa Dotti, Antonio Federico.   

Abstract

The Zellweger spectrum disorders (ZSDs) are known to be severe disorders with onset in the newborn period or later in childhood, frequently resulting in death during childhood or adolescence. Here, we report a case of ZSD due to mutations in the PEX2 gene, with very mild phenotype. A 51-year-old Italian man was referred to us because of a clinical picture characterized by ataxia, areflexia, nystagmus, and strabismus, with childhood onset and slowly progressive course. The patient showed no cognitive impairment. Neurological examination revealed gait ataxia, dysarthria, dysmetria, areflexia, and bilateral pes cavus. Nerve conduction studies indicated a severe axonal sensorimotor polyneuropathy. Brain MRI showed marked cerebellar atrophy and absence of white matter involvement. MR spectroscopy uncovered a decreased N-acetyl aspartate peak. Biochemical analyses suggested a mild peroxisomal defect. Sequence analysis of the PEX2 gene identified two heterozygous mutations. The clinical phenotype of our patient differs from previously reported ZSD patients with PEX2 gene mutations and suggests that genetic screening of PEX2 is warranted in children and adults with otherwise unexplained autosomal recessive ataxia. MRI findings diverged from the "classic" spectrum observed in ZSDs. The moderate impairment in peroxisome biogenesis seems to affect predominantly neuronal cells in cerebellum, leading to cerebellar atrophy.

Entities:  

Year:  2012        PMID: 23430938      PMCID: PMC3565677          DOI: 10.1007/8904_2011_102

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  13 in total

1.  Biochemical markers predicting survival in peroxisome biogenesis disorders.

Authors:  J Gootjes; P A W Mooijer; C Dekker; P G Barth; B T Poll-The; H R Waterham; R J A Wanders
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

2.  Identification of an unusual variant peroxisome biogenesis disorder caused by mutations in the PEX16 gene.

Authors:  Merel S Ebberink; Barbara Csanyi; Wui K Chong; Simone Denis; Peter Sharp; Petra A W Mooijer; Conny J M Dekker; Claire Spooner; Lock H Ngu; Carlos De Sousa; Ronald J A Wanders; Michael J Fietz; Peter T Clayton; Hans R Waterham; Sacha Ferdinandusse
Journal:  J Med Genet       Date:  2010-07-20       Impact factor: 6.318

Review 3.  Peroxisome biogenesis disorders.

Authors:  Steven J Steinberg; Gabriele Dodt; Gerald V Raymond; Nancy E Braverman; Ann B Moser; Hugo W Moser
Journal:  Biochim Biophys Acta       Date:  2006-09-14

Review 4.  Peroxisomal protein translocation.

Authors:  Wolfgang Girzalsky; Delia Saffian; Ralf Erdmann
Journal:  Biochim Biophys Acta       Date:  2010-01-13

Review 5.  Mutations in PEX10 are a cause of autosomal recessive ataxia.

Authors:  Luc Régal; Merel S Ebberink; Nathalie Goemans; Ronald J A Wanders; Linda De Meirleir; Jacques Jaeken; Maarten Schrooten; Rudy Van Coster; Hans R Waterham
Journal:  Ann Neurol       Date:  2010-08       Impact factor: 10.422

6.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.

Authors:  N De Stefano; S Narayanan; G S Francis; R Arnaoutelis; M C Tartaglia; J P Antel; P M Matthews; D L Arnold
Journal:  Arch Neurol       Date:  2001-01

7.  Novel mutations in the PEX2 gene of four unrelated patients with a peroxisome biogenesis disorder.

Authors:  Jeannette Gootjes; Orly Elpeleg; François Eyskens; Hanna Mandel; Delphine Mitanchez; Noboyuki Shimozawa; Yasuyuki Suzuki; Hans R Waterham; Ronald J A Wanders
Journal:  Pediatr Res       Date:  2003-11-19       Impact factor: 3.756

8.  Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients.

Authors:  Bwee Tien Poll-The; Jeannette Gootjes; Marinus Duran; Johannis B C De Klerk; Liesbeth J Maillette de Buy Wenniger-Prick; Ronald J C Admiraal; Hans R Waterham; Ronald J A Wanders; Peter G Barth
Journal:  Am J Med Genet A       Date:  2004-05-01       Impact factor: 2.802

9.  Cerebral MRI as a valuable diagnostic tool in Zellweger spectrum patients.

Authors:  S Weller; H Rosewich; J Gärtner
Journal:  J Inherit Metab Dis       Date:  2008-04-14       Impact factor: 4.982

10.  Neuroimaging of peroxisome biogenesis disorders (Zellweger spectrum) with prolonged survival.

Authors:  P G Barth; C B L M Majoie; J Gootjes; R J A Wanders; H R Waterham; M S van der Knaap; J B C de Klerk; J Smeitink; B T Poll-The
Journal:  Neurology       Date:  2004-02-10       Impact factor: 9.910

View more
  17 in total

Review 1.  Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.

Authors:  Nancy E Braverman; Gerald V Raymond; William B Rizzo; Ann B Moser; Mark E Wilkinson; Edwin M Stone; Steven J Steinberg; Michael F Wangler; Eric T Rush; Joseph G Hacia; Mousumi Bose
Journal:  Mol Genet Metab       Date:  2015-12-23       Impact factor: 4.797

2.  Eye movement abnormalities in a patient with Zellweger spectrum disorder.

Authors:  F Rosini; C Vinciguerra; A Mignarri; M Di Giovanni; A Federico; A Rufa
Journal:  Neurol Sci       Date:  2016-02-05       Impact factor: 3.307

Review 3.  Peroxisome Biogenesis Disorders.

Authors:  Masanori Honsho; Kanji Okumoto; Shigehiko Tamura; Yukio Fujiki
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Mild Zellweger syndrome due to a novel PEX6 mutation: correlation between clinical phenotype and in silico prediction of variant pathogenicity.

Authors:  Małgorzata Rydzanicz; Teresa Joanna Stradomska; Elżbieta Jurkiewicz; Ewa Jamroz; Piotr Gasperowicz; Grażyna Kostrzewa; Rafał Płoski; Anna Tylki-Szymańska
Journal:  J Appl Genet       Date:  2017-10-18       Impact factor: 3.240

Review 5.  Peroxisomes take shape.

Authors:  Jennifer J Smith; John D Aitchison
Journal:  Nat Rev Mol Cell Biol       Date:  2013-12       Impact factor: 94.444

6.  Lipidomic analysis of fibroblasts from Zellweger spectrum disorder patients identifies disease-specific phospholipid ratios.

Authors:  Katharina Herzog; Mia L Pras-Raves; Martin A T Vervaart; Angela C M Luyf; Antoine H C van Kampen; Ronald J A Wanders; Hans R Waterham; Frédéric M Vaz
Journal:  J Lipid Res       Date:  2016-06-09       Impact factor: 5.922

7.  Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders.

Authors:  Femke C C Klouwer; Sacha Ferdinandusse; Henk van Lenthe; Wim Kulik; Ronald J A Wanders; Bwee Tien Poll-The; Hans R Waterham; Frédéric M Vaz
Journal:  J Inherit Metab Dis       Date:  2017-07-04       Impact factor: 4.982

8.  Gene-based meta-analysis of genome-wide association studies implicates new loci involved in obesity.

Authors:  Sara Hägg; Andrea Ganna; Sander W Van Der Laan; Tonu Esko; Tune H Pers; Adam E Locke; Sonja I Berndt; Anne E Justice; Bratati Kahali; Marten A Siemelink; Gerard Pasterkamp; David P Strachan; Elizabeth K Speliotes; Kari E North; Ruth J F Loos; Joel N Hirschhorn; Yudi Pawitan; Erik Ingelsson
Journal:  Hum Mol Genet       Date:  2015-09-16       Impact factor: 6.150

9.  Clinical, neuroradiological, and molecular characterization of patients with atypical Zellweger spectrum disorder caused by PEX16 mutations: a case series.

Authors:  Anthony Cheung; Catherine Argyriou; Christine Yergeau; Yasmin D'Souza; Émilie Riou; Sébastien Lévesque; Gerald Raymond; Mebratu Daba; Irakli Rtskhiladze; Tinatin Tkemaladze; Laura Adang; Roberta La Piana; Geneviève Bernard; Nancy Braverman
Journal:  Neurogenetics       Date:  2022-02-02       Impact factor: 2.660

10.  A homozygous mutation in PEX16 identified by whole-exome sequencing ending a diagnostic odyssey.

Authors:  Carlos Bacino; Yu-Hsin Chao; Elaine Seto; Tim Lotze; Fan Xia; Richard O Jones; Ann Moser; Michael F Wangler
Journal:  Mol Genet Metab Rep       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.